Volume 22, No 4, Apr 2012

ISSN: 1001-0602 
EISSN: 1748-7838 2018 
impact factor 17.848* 
(Clarivate Analytics, 2019)

Volume 22 Issue 4, April 2012: 620-623

RESEARCH HIGHLIGHTS

Defining the expressed breast cancer kinome

Alicia A Midland¹, Martin C Whittle², James S Duncan², Amy N Abell², Kazuhiro Nakamura², Jon S Zawistowski², Lisa A Carey³, H Shelton Earp III³, Lee M Graves

¹Biomedical Engineering and Curriculum in Bioinformatics and Computational Biology, Lineberger Comprehensive Cancer Center, University of North Carolina School of Medicine, Chapel Hill, NC 27599, USA
²Department of Pharmacology, Lineberger Comprehensive Cancer Center, University of North Carolina School of Medicine, Chapel Hill, NC 27599, USA
³Department of Medicine, Lineberger Comprehensive Cancer Center, University of North Carolina School of Medicine, Chapel Hill, NC 27599, USA Correspondence: Gary L Johnson,(glj@med.unc.edu)

Protein kinases are arguably the most tractable candidates for development of new therapies to treat cancer. Deep sequencing of breast cancer cell lines indicates each express 375 or so kinases, representing nearly 75% of the kinome. A rich network both downstream and upstream from key oncogenic kinases includes both tyrosine and serine/threonine kinases, giving plasticity and resiliency to the cancer cell kinome.

Cell Research (2012) 22:620-623. doi:10.1038/cr.2012.25; published online 7 February 2012

FULL TEXT | PDF

Browse 1998